The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...

The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, ...

The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, designed to treat amyotrophic lateral sclerosis (ALS), after the FDA lifted its ...

The Swedish biotech hopes its precision therapy will help patients with advanced solid tumors who currently have few treatment options.

Diane Lacroix, Vice President of Clinical Data Management at eClinical Solutions, talks personalised medicine, data decisions and AI ...